Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG -3.56%54 3-1 Month Momentum % is 112.78% as of Aug. 17, 2026. GuruFocus rates TXG with a GF Score™ of 54/100 and a GF Value™ of $18.38 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 676 Healthcare Providers & Services companies, 10x Genomics ranks better than 99.7% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), 10x Genomics's 3-1 Month Momentum % is 112.78%.
The industry rank for 10x Genomics's 3-1 Month Momentum % or its related term are showing as below:
TXG's 3-1 Month Momentum % is ranked better than 99.7% of 676
companies
in the Healthcare Providers & Services industry
Industry Median: -2.515
vs TXG: 112.78
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
10x Genomics 3-1 Month Momentum % Related Terms
TXG vs HNGE, WAY, TEM: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, 10x Genomics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a 3-1 Month Momentum % of 112.78% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #2 out of 676 companies in the Healthcare Providers & Services industry, placing it in the top 0.3%.
Is 10x Genomics' 3-1 Month Momentum % too high?
10x Genomics' current 3-1 Month Momentum % is 112.78%. Based on the distribution chart, 10x Genomics ranks #2 out of 676 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' 3-1 Month Momentum % compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #2 out of 676 companies for 3-1 Month Momentum %. This places 10x Genomics in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on 10x Genomics and its competitors. 10x Genomics's current 3-1 Month Momentum % is 112.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.38, compared to a current price of $56.08 — trading 205.1% above its estimated fair value. The current 3-1 Month Momentum % is 112.78%. 10x Genomics' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For 10x Genomics (TXG), the current 3-1 Month Momentum % is 112.78% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $56.08 is trading 205.1% above its estimated GF Value™ of $18.38.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
3-1 Month Momentum %: 112.78%
GF Value™: $18.38 vs. price of $56.08 (205.1% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
54GF Score
Get the complete analysis for TXG
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
